Msc Student University of surrey Guildford, England, United Kingdom
Introduction: Targeted nanocarriers improve drug accumulation but often fail to ensure selective activation at the disease site. Rifampicin delivery is limited by poor tissue penetration and systemic toxicity, necessitating targeted nanocarrier systems with improved loading and controlled release [3]. This study evaluates mesoporous silica nanostars (MSiNS) as high-capacity carriers [2] and explores whether their release behaviour can inform a shift from localisation-driven delivery toward condition-dependent activation strategies.
Learning Objectives:
Describe how nanostar morphology influences rifampicin loading efficiency across solvent systems.
Explain the biphasic release behaviour of rifampicin from mesoporous silica nanostars in vitro.
Justify the shift from localization driven delivery to damage state dependent activation strategies
